Who are Slow dose preemptive Atropine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atropine 0.04%, Atropine Sulfate 1% Oph Soln, Atropine 0.01%, Atropine Ophthalmic 0.05%, Atropine Ophthalmic 0.5%, Atropine Sulfate 03.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/slow-dose-preemptive-atropine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Slow dose preemptive Atropine — Competitive Intelligence Brief

Slow dose preemptive Atropine (Slow dose preemptive Atropine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent / Muscarinic antagonist. Area: Toxicology / Emergency Medicine.

marketed Anticholinergic agent / Muscarinic antagonist Muscarinic acetylcholine receptors (M1-M5) Toxicology / Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Slow dose preemptive Atropine (Slow dose preemptive Atropine) — Abant Izzet Baysal University. Slow dose preemptive atropine blocks muscarinic acetylcholine receptors to prevent cholinergic toxicity and organophosphate poisoning effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Slow dose preemptive Atropine TARGET	Slow dose preemptive Atropine	Abant Izzet Baysal University	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine 0.04%	Atropine 0.04%	Beijing Tongren Hospital	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine Sulfate 1% Oph Soln	Atropine Sulfate 1% Oph Soln	State University of New York College of Optometry	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1, M3)
Atropine 0.01%	Atropine 0.01%	University Hospital, Strasbourg, France	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Atropine Ophthalmic 0.05%	Atropine Ophthalmic 0.05%	Erasmus Medical Center	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3)
Atropine Ophthalmic 0.5%	Atropine Ophthalmic 0.5%	Erasmus Medical Center	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3)
Atropine Sulfate 03	Atropine Sulfate 03	LitePharmTech Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent / Muscarinic antagonist class)

Erasmus Medical Center · 2 drugs in this class
LitePharmTech Co., Ltd. · 2 drugs in this class
Abant Izzet Baysal University · 1 drug in this class
Beijing Tongren Hospital · 1 drug in this class
State University of New York College of Optometry · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Slow dose preemptive Atropine — Competitive Intelligence Brief. https://druglandscape.com/ci/slow-dose-preemptive-atropine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab